All News

Canada.maple.leaf

ICYMI: Updated CRA/SPARCC Recommendations for Axial Spondyloarthritis

Jack Cush, MD

In 2024, the Canadian Rheumatology Association (CMA) and the Spondyloarthritis Research Consortium of Canada (SPARCC) published a comprehensive set of 56 treatment recommendations for the management of axial spondyloarthritis. This first update is focused on the reassessment of IL-17i recommendations.

Read Article
ILD damage fibrosis path

EULAR26: ANCHOR-RA Study of RA-ILD

EurekAlert!

People with rheumatoid arthritis are at risk of developing interstitial lung disease (RA-ILD), which is associated with high mortality.

Read Article
Giant-Cell_Vasculitis.jpg

EULAR26: Vasculitis updates: Glucorticoid use in AAV and GCA

EurekAlert!

EULAR recommends a combination of glucocorticoids with either rituximab or cyclophosphamide for remission induction in life-threatening or organ-threatening AAV, followed by gradual tapering of glucocorticoids.

Read Article
uricacid.jpg

ICYMI: Worldwide Trends in Hyperuricemia

Jack Cush, MD

A Lancet Rheumatology systematic review shows the prevalence of hyperuricaemia has risen markedly over the past two decades in both men and women, owing to population growth, aging, and increasing age-specific rates

Read Article
laptop image

Insights into Treating Lupus - A Rheum Survey 

Jack Cush, MD

RheumNow recently surveyed clinicians to better understand current practice patterns, educational needs, and barriers to the use of new, advanced therapies in systemic lupus erythematosus (SLE). A total of 197 clinicians completed the survey.

Read Article
GLP-1.pink

EULAR26: GLP-1 Agonist Use in the RISE Registry

EurekAlert!

At EULAR 2026, McCormick and Curtis et al presented data from the American College of Rheumatology’s (ACR) Rheumatology Informatics System for Effectiveness (RISE) registry on the use of GLP-1 agents in rheumatic diseases (RMD). 

Read Article
Vexas

ICYMI: VEXAS Syndrome - A Review

Jack Cush, MD

Beck et al has published a review of the VEXAS syndrome in The Lancet, focusing on the pathogenesis, spectrum, and treatment strategies.

Read Article
RT @aurelierheumo A long release version of xanthine oxidase inhibitor in gout -442 pts 36 wks -HR091506 vs febuxostat -SUA <300 μmol/L: 63.8% vs 40.7% (Δ +22.9%, p<0.0001) -higher SUA reduction vs baseline -Similar overall TEAEs (~90%) A molecule to keep an eye on! #LB0008

Dr. John Cush RheumNow ( View Tweet)

NEW FROM EULAR: A real-world analysis of predictors of IBD in PsA. 🔎 In patients with PsA, signs and symptoms of IBD may appear before diagnosis, but do we know what to look for? Explore the poster: https://t.co/x2pM0T9LWg Sponsored by AbbVie Medical Affairs + Health Impact.

Links:

Dr. John Cush RheumNow ( View Tweet)

DERM on RheumNow (June 2026) The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biologics, JAKs - their use, efficacy and side effects. https://t.co/vy4BAx8Lnq
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Glucocorticoid Injections in Knee Osteoarthritis A randomized clinical trial of 60 patients found that glucocorticoid injections into the infrapatellar fat pad (IPFP) did not significantly reduce pain scores in patients with inflammatory knee osteoarthritis (compared to https://t.co/QhW7CMx72x
Dr. John Cush RheumNow ( View Tweet)
ICYMI: EGPA Review A current review of eosinophilic granulomatosis with polyangiitis (EGPA) provides current recommendations on diagnosis and management. https://t.co/rFGoYBMwCP https://t.co/U0HRR7XeVT

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: 2025 Update: EULAR Recommendations on Rheumatoid Arthritis Management EULAR has updated their rheumatoid arthritis (RA) management recommendations, notably with fewer recommendations (total of 9, down from 11 in 2022 version), by merging and removing previous https://t.co/6WAZB1dOpI
Dr. John Cush RheumNow ( View Tweet)
ICYMI: B Cells at the Brink in Sjögren Disease The current issue of Arthritis & Rheumatology reviews current understanding of the immunopathogenesis of Sjögren disease (SjD) and how that has influenced the quest for drug development for this most systemic autoimmune disorder. https://t.co/OBFqHYof5m
Dr. John Cush RheumNow ( View Tweet)
RT @minidey #OP0342 Interim real-world ASTER data showed anifrolumab improved overall SLEDAI-2K scores & reduced disease activity across multiple organ systems over 12 months, particularly mucocutaneous &amp; MSK domains. Nearly 30% achieved SLEDAI-2K=0 at 1 year. #EULAR2026

Dr. John Cush RheumNow ( View Tweet)

RT @aurelierheumo Failure to achieve early remission RA asso w/ non-inflammatory pain NORD-STAR 526 early RA pts) no remission at 24 wks increased risk of 48wk • unacceptable pain (OR ~6) • refractory pain (OR ~6) • fibromyalgic RA (OR ~16) Signal strongest w/ very early

Dr. John Cush RheumNow ( View Tweet)

EULAR26: Reports on Systemic Sclerosis https://t.co/knZZlMYlen https://t.co/0wul0yaw4m

Links:

Dr. John Cush RheumNow ( View Tweet)
Generic Tofacitinib (6.26.2026) Dr. Jack Cush reviews the news and journal articles from https://t.co/V10S4oVFsv. Updates on tofacitinib, CAR-T therapy and AI. https://t.co/DNWh7taaN6 https://t.co/4r5fuooqWn

Links:

Dr. John Cush RheumNow ( View Tweet)
EULAR26: Updates in SLE and APS Severe refractory systemic lupus erythematosus (srSLE) is a clinical state conceptualised as persistent high disease activity despite standard care with glucocorticoids and immunosuppressants. https://t.co/DP7gPvlGhU https://t.co/imN6Xb7QGT

Links:

Dr. John Cush RheumNow ( View Tweet)
Is it all over for avacopan? #Vasculitis https://t.co/1sFUidC6Cw

Links:

Rheuma Doc LastManStand85 ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×